![](/img/cover-not-exists.png)
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials
Wolchok, J. D., Weber, J. S., Maio, M., Neyns, B., Harmankaya, K., Chin, K., Cykowski, L., de Pril, V., Humphrey, R., Lebbe, C.Volume:
24
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdt161
Date:
August, 2013
File:
PDF, 170 KB
english, 2013